LACOSACOR; LACOVIM; PHARMACOR LACOSAMIDE; VIMCOSA (Pharmacor Pty Ltd)
Product name
LACOSACOR; LACOVIM; PHARMACOR LACOSAMIDE; VIMCOSA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
152 (255 working days)
Active ingredients
lacosamide
Registration type
New generic medicine
Indication
LACOSACOR; LACOVIM; PHARMACOR LACOSAMIDE; VIMCOSA (film-coated tablet) are indicated as:
- monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.
- add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.
- add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.